After submitting this required documentation in the IND/NDA/BLA, is the sponsor required to submit IEC actions on continuing review to FDA?

No, although continuing review by the IEC is required under 21 CFR 312.120(a)(1)(i), documentation of such review need not be submitted under 21 CFR 312.120(b)(7). However, such continuing review information should be maintained and available to FDA upon request.